GlassScriptPhysician profile
Amanda S Kapper
NPI 1689045171
$4,868.54
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $645 · 2022: $3,486 · 2023: $456 · 2024: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $2,714.95 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $493.44 | 2021-2024 | Lifevest |
| Abbvie INC. | $349.78 | 2021-2022 | |
| Novo Nordisk INC | $209.84 | 2021-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $187.34 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $170.05 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.77 | 2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $104.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $96.86 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $95.53 | 2023 | Uptravi, Opsumit |
| Sk Life Science, INC. | $90.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $86.58 | 2021 | |
| Pfizer INC. | $18.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Kapper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.